Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Price$11.08Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $881,705 | $3.9M | $36.1M | $4.8M | $2.4M | $1.9M | $648,382 | — | — |
| Research & development | $70.1M | $32.2M | $31.2M | $16.1M | $36.4M | $98.3M | $89.6M | $48.6M | $26.0M | $15.4M | $5.9M | $1.3M | $210,670 |
| Operating expenses | $85.3M | $48.7M | $45.1M | $39.8M | $56.9M | $126.7M | $113.2M | $61.6M | $35.0M | $21.9M | $9.5M | $2.6M | $557,276 |
| Operating income | −$85.3M | −$48.7M | −$45.1M | −$39.8M | −$56.0M | −$122.8M | −$77.1M | −$56.7M | −$32.6M | −$20.0M | −$8.9M | −$2.6M | −$557,276 |
| Operating margin | — | — | — | — | −6,350.09% | −3,119.20% | −213.33% | −1,176.78% | −1,334.43% | −1,045.56% | −1,365.51% | — | — |
| EBITDA | −$85.1M | −$48.1M | −$44.4M | −$39.1M | −$55.0M | −$121.7M | −$76.4M | −$56.3M | −$32.3M | −$19.9M | −$8.8M | −$2.6M | — |
| EBITDA margin | — | — | — | — | −6,236.69% | −3,090.66% | −211.28% | −1,166.54% | −1,323.96% | −1,040.97% | −1,358.73% | — | — |
| Net income | −$78.5M | −$40.2M | −$44.6M | −$42.3M | −$45.6M | −$111.3M | −$71.5M | −$55.7M | −$32.4M | −$20.0M | −$8.9M | −$2.5M | −$602,350 |
| Net profit margin | — | — | — | — | −5,176.38% | −2,826.08% | −197.69% | −1,154.48% | −1,328.65% | −1,046.27% | −1,365.05% | — | — |
| Basic EPSper basic share | -$5.90 | -$3.68 | -$10.31 | -$10.15 | -$11.15 | -$42.60 | -$33.60 | -$29.40 | -$19.50 | -$14.70 | -$8.40 | -$3.90 | -$2.70 |
| Diluted EPSper diluted share | -$5.90 | -$3.68 | -$10.31 | -$10.15 | -$11.15 | -$42.60 | -$33.60 | -$29.40 | -$19.50 | -$14.70 | -$8.40 | -$3.90 | -$2.70 |
Owners
Reported shareholders
12.56%of listed shares
Cormorant Asset Management, LP2.34M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Cormorant Asset Management, LP | 12.56%2.34M shares |
ORBIMED ADVISORS LLC | 9.30%1.74M shares |
BlackRock, Inc. | 7.13%1.33M shares |
Aberdeen Group plc | 7.08%1.32M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.08%760.94K shares |
Jones Hill Capital LP | 3.50%653.57K shares |
Prosight Management, LP | 3.48%650K shares |
Stonepine Capital Management, LLC | 2.28%425K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.27%423.37K shares |
ADAR1 Capital Management, LLC | 2.26%421.79K shares |
DIADEMA PARTNERS LP | 1.61%301.26K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.57%293.2K shares |
STATE STREET CORP | 1.36%254.67K shares |
DIMENSIONAL FUND ADVISORS LP | 1.02%190.21K shares |
Exome Asset Management LLC | 0.99%184.91K shares |
Cohen Yuval | ≈0.93%174.32K shares |
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 0.81%151.64K shares |
JANE STREET GROUP, LLC | 0.75%139.13K shares |
NORTHERN TRUST CORP | 0.67%124.91K shares |
VANGUARD FIDUCIARY TRUST CO | 0.60%112.4K shares |
Percentages use 18.67M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 10, 2026Form 4 · 10b5-1 | Kung WinstonDirector | SellCommon Stock, par value $0.0001 per share | 2.0K | $7.91 | $16.0K | 12.1K |
| Jun 10, 2026Form 4 · 10b5-1 | Jenkins John KennethDirector | SellCommon Stock, par value $0.0001 per share | 4.8K | $7.91 | $38.0K | 3.8K |
| Jun 10, 2026Form 4 · 10b5-1 | Altmeyer AnneDirector | SellCommon Stock, par value $0.0001 per share | 2.4K | $7.91 | $19.1K | 7.6K |
| Jun 3, 2026Form 4 | Saxena Nishant CChief Business Officer | BuyCommon Stock, par value $0.0001 per share | 9.0K | $7.58 | $68.2K | 75.3K |
| Jun 2, 2026Form 4 | Saxena Nishant CChief Business Officer | BuyCommon Stock, par value $0.0001 per share | 4.5K | $7.33 | $33.0K | 66.3K |